·ÇÎüÑÌÕß,nonsmokersÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ï¸Ö§Æø¹Ü·ÎÅÝ/²¡Àíѧ,bronchiolo-alveolar/patholÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ºËÌǺËÜÕËáÀà,ribonucleotidesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹ÃÏ¢·ÅÁÆ,RadiotheropyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¢óÆÚNSCLC,NSCLCÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×éÖ¯µ°°×øD(CathD),cathDÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 32P-½ºÌå,32P-colloidÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« GGTase-I»ùÒò,GGTase-IÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« FTase»ùÒò,FTaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ó°ÏñÒýµ¼·ÅÁÆ,IGRTÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °±ëÄøN/CD13,APN/CD13Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ±£·ÎÌÀ,baofeitangtherapymethodÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 5-µªÍÑÑõ°ûÜÕ,5-aza-2'-deoxyeytidineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °±»ùÄ©¶ËëÄ,N-telopeptideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÚÍÌ·ÖÑ¡,EndosomesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Rad51µ°°×,Rad51Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×é°·-ßÅßáÃÀÐÁ,His-INÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼ª·ÇÌæÄá(Ò×Èðɳ),Gefitinib(Iressa)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿ÂÈøÆæÏÙ²¡¶¾ÊÜÌå(CAR),CD46Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« µç×ÓÆø¹Ü¾µ,electrobronchoscopeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼¡Áö/·Î,Leiomyoma/lungÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼¡Áö/×Ó¹¬,Leiomyoma/uterusÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ß²·ÔÄ·ÄÆ,PHOTOFRINÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »¯ÁÆÏà¹ØÐÔ°×ϸ°û¼õÉÙ,CILÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 131I-Ö×Áöϸ°ûºËÈËÊóǶºÏµ¥¿Ë¡¿¹Ìå,131I-chTNTÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¦Á-°ëÈéÌÇ»ù,¦Á-galactosyl(¦Á-gal)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« pT1ÆÚ,pT1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« 18·úÍÑÑõÆÏÌÑÌÇ,18fluorodeoxylucoseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µÍÉøÎÂÈÈ»¯ÁÆ,Hyperthermo-chemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ²¼Â³Éú,brucineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« CD44µ¥¿¹,CD44McAbÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« È¥ÕûºÏËØ-½ðÊôµ°°×ø8,ADAM8Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« GP·½°¸»¯ÁÆ,GPchemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »ùÖʽðÊôµ°°×ø2(MMP-2),matrixMetalloproteinase-2(MMP-2)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« E¸Æð¤¸½µ°°×,E-cadherineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ñ»µ¨×ÓÈéÓÍ×¢ÉäÒº,Ya-Dan-ZiÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Wip1»ùÒò,Wip1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·Ö´ÎÓ¦ÓÃ,dividedÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼ÁÁ¿´¦·½(DP),dose-prescription(DP)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« º¬Äδﲬ,NedaplatinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼ªÎ÷Ëû±õ/˳²¬,Cisplatin/gemcitabineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ĥ¸½×ÅÐͱ¾ÌåA2,Ephrin-A2Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ΢СRNA-21,miRNA-21Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼××´ÏÙÔËÔØµ°°×,TransthyretinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°û×ÔÉí·Ö»¯¿¹Ô­-1,CDA1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¾ÖÔîÐÔÄ¥²£Á§Õ÷,GGOÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ABCE1»ùÒò,ABCE1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ĥϸ°û¹Ç¼ÜÁ¬½Óµ°°×,EzrinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ԭʼ/Õï¶Ï,Primitive/diagnosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Reprimo»ùÒò,ReprimoÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« tuberinµ°°×,TuberinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÎÑÒÄþ,FeiyanningÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°û½Çµ°°×19-mRNA,cytokeratin19-mRNAÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈËÀà×ÅÉ«ÐÔ¸ÉÆ¤²¡»ùÒòD,XPD/ERCC2Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ²ÝËᲬ/³¤´ºÈð±õ,L-OHP/NVBÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸ÉÈÅËØ¼¤»î»ùÒò,ISGsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÚÆ¤Ï¸°ûÌØÒì·Ö×Ó-1,endocanÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ʳ¹Ü·ÅÉäËðÉË,EsophagustoxicityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ͼÏñÅä×¼,image registrationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÁÛ״ϸ°û,Squamous CellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÁܰÍ×ªÒÆ,lymphatic metastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Áܰͽá×ªÒÆ,lymph node metastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÒýÎÄ·ÖÎö,citation analysisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×Áö·ÖÆÚ,Neoplasm StagingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÇСϸ°û·Î°©,Non-small cell lung cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×ÁöÇÖÈó,Neoplasm invasivenessÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ҽѧͼÏñÅä×¼,Medical image registrationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¾Ö²¿¸´·¢,Local recurrenceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÅàÑøµÄÖ×Áöϸ°û,cultured tumor cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µ°°×ÖÊP16,Protein P16Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈýάÊÊÐηÅÁÆ,three-dimensional conformal radiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÎÄÍÒ©µ°°×,Lung resistance proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« TNM·ÖÆÚ,TNM stagingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« СÁºÏ¸°û,trabecular meshwork cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÇСϸ°û·Î/·ÅÉäÁÆ·¨,non-small cell lung/radiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Kai1»ùÒò,Kai1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« RUNX3»ùÒò,RUNX3 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÔ×ªÒÆ,brain metastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »¬Ä¤ÈâÁö,Synovial sarcomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Áܰ͹ÜÃܶÈ,Lymphatic vessel densityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÖÇÄÜʶ±ð,intelligent recognitionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« CD44v6µ°°×,CD44v6 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« p21wAF1,p21 WAF1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« KDRÆô¶¯×Ó,KDR promoterÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ΢ÎÀÐÇÖØ¸´,Microsatellite repeatsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Àà°©Áö,carcinoid tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ï¸Ö§Æø¹Ü·ÎÅݰ©,bronchioloalveolar carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Fhitµ°°×,Fhit proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« FisherÅбð·ÖÎö,Fisher discriminant analysisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÊÊÐηÅÉäÖÎÁÆ,conformal radiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ΢Áܰ͹ÜÃܶÈ,lymphatic microvessel densityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« nm23-H1µ°°×,nm23-H1 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×ÁöÒÖÖÆµ°°×ÖÊÀà,Tumor suppressor proteinsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ó²»¯ÐÔѪ¹ÜÁö,Sclerosing hemangiomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« hMLH1»ùÒò,hMLH1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« NP·½°¸,NP regimenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ͬÆÚ·Å»¯ÁÆ,Concurrent chemoradiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÎÖ×Áö/·ÅÉäÉãÓ°Êõ,Lung Neoplasms/radiographyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ki-67µ°°×,Ki-67 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Сϸ°û·Î,small cell lungÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«